Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model. Alzheimer's & Dementia: Translational Research & Clinical Interventions, Volume 4, 2018, Pages 488-498.

https://www.trci.alzdem.com/article/S2352-8737(18)30022-2/abstract

https://www.ncbi.nlm.nih.gov/pubmed/30338290

Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation. Front Aging Neurosci. 2019 Jan 25;10:432.

https://dx.doi.org/10.3389%2Ffnagi.2018.00432

Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease. Mol Neurobiol. 2017;54(10):8063–8070.

https://www.ncbi.nlm.nih.gov/pubmed/27889894

Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis: 

https://www.ncbi.nlm.nih.gov/pubmed/25652642

Novel Nuclear Factor-KappaB Targeting Peptide Suppresses β-Amyloid Induced Inflammatory and Apoptotic Responses in Neuronal Cells. PLoS One. 2016;11(10):e0160314.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072831/

Functional characterization of a competitive peptide antagonist of p65 in human macrophage-like cells suggests therapeutic potential for chronic inflammation: 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262379/

CD80 Blockade Enhance Glucocorticoid-Induced Leucine Zipper Expression and Suppress Experimental Autoimmune Encephalomyelitis: 

http://www.jimmunol.org/content/183/11/7505.long